Abstract: Methods of treating patients having varicose veins, methods of identifying subjects having an increased risk of developing varicose veins, and methods of diagnosing varicose veins in a human subject, comprising detecting the presence of Piezo Type Mechanosensitive Ion Channel Component 1 (PIEZO1) predicted loss-of-function variant nucleic acid molecules and polypeptides in a biological sample from the patient or subject, are provided herein.

Abstract: The present disclosure provides methods of treating a subject having a kidney disease or preventing a subject from developing a kidney disease, and methods of identifying subjects having an increased risk of developing a kidney disease.

Abstract: The present disclosure provides methods of treating subjects having an inflammatory disease, and methods of identifying subjects having an increased risk of developing an inflammatory disease.

Abstract: Methods of treating patients having varicose veins, methods of identifying subjects having an increased risk of developing varicose veins, and methods of diagnosing varicose veins in a human subject, comprising detecting the presence of Piezo Type Mechanosensitive Ion Channel Component 1 (PIEZO1) predicted loss-of-function variant nucleic acid molecules and polypeptides in a biological sample from the patient or subject, are provided herein.

Abstract: The present disclosure provides methods of treating subjects having varicose veins or at risk of developing varicose veins, methods of identifying subjects having an increased risk of developing varicose veins, and methods of detecting Piezo Type Mechanosensitive Ion Channel Component 1 (PIEZO1) variant nucleic acid molecules and variant polypeptides.

Abstract: The present disclosure provides methods of treating a subject having asthma or at risk of developing asthma, and methods of identifying subjects having an increased risk of developing asthma.

Abstract: The present disclosure provides methods of treating subjects having hypertension, coronary heart disease, and/or atrial fibrillation or at risk of developing hypertension, coronary heart disease, and/or atrial fibrillation, methods of identifying subjects having an increased risk of developing hypertension, coronary heart disease, and/or atrial fibrillation, and methods of detecting Solute Carrier Family 9 Isoform A3 Regulatory Factor 2 (SLC9A3R2) variant nucleic acid molecules and variant polypeptides.

Abstract: The present disclosure provides methods of treating a subject having a metabolic disorder or is at risk of developing a metabolic disorder or preventing a subject from developing a metabolic disorder, and methods of identifying subjects having an increased risk of developing a metabolic disorder.

Abstract: The present disclosure provides methods of treating subjects having skin cancer or at risk of developing skin cancer, and methods of identifying subjects having an increased risk of developing skin cancer.

Abstract: A chalk line marking device, including a main body, including a first section disposed on at least a portion of a first end of the main body, and a second section disposed on at least a portion of a second end of the main body, a handle disposed between the first section and the second section to facilitate gripping thereof, and a chalk string disposed within at least a portion of the main body and the handle, and around a first tip of the main body and a second tip of the main body to move the first section and the second section from bent in a first position to at least partially extended in a second position, such that the chalk string creates a chalk line in response to movement of the first section and the second section.

Abstract: A chalk line marking device, including a main body, including a first section disposed on at least a portion of a first end of the main body, and a second section disposed on at least a portion of a second end of the main body, a handle disposed between the first section and the second section to facilitate gripping thereof, and a chalk string disposed within at least a portion of the main body and the handle, and around a first tip of the main body and a second tip of the main body to move the first section and the second section from bent in a first position to at least partially extended in a second position, such that the chalk string creates a chalk line in response to movement of the first section and the second section.

Abstract: The disclosure provides nucleic acid molecules, including cDNA, comprising an alteration that encodes variant human Solute Carrier Family 14 Member 1 (SLC14A1) proteins that associate with protection against coronary artery disease (CAD). The disclosure also provides methods for classifying subjects at risk of developing a coagulation condition, based on the identification of such alterations.

Abstract: Methods of treating patients having varicose veins, methods of identifying subjects having an increased risk of developing varicose veins, and methods of diagnosing varicose veins in a human subject, comprising detecting the presence of Piezo Type Mechanosensitive Ion Channel Component 1 (PIEZO1) predicted loss-of-function variant nucleic acid molecules and polypeptides in a biological sample from the patient or subject, are provided herein.

Abstract: Methods of treating patients having decreased bone mineral density and/or osteoporosis, methods of identifying subjects having an increased risk of developing decreased bone mineral density and/or osteoporosis, and methods of diagnosing decreased bone mineral density and/or osteoporosis in a human subject, comprising detecting the presence of Matrix Extracellular Phosphoglycoprotein (MEPE) predicted loss-of-function variant nucleic acid molecules and polypeptides in a biological sample from the patient or subject, are provided herein.

Abstract: The disclosure provides nucleic acid molecules, including cDNA, comprising an alteration that encodes variant human Solute Carrier Family 14 Member 1 (SLC14A1) proteins that associate with protection against coronary artery disease (CAD). The disclosure also provides methods for classifying subjects at risk of developing a coagulation condition, based on the identification of such alterations.